Skip to main content
Journal cover image

Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.

Publication ,  Journal Article
Bali, DS; Goldstein, JL; Banugaria, S; Dai, J; Mackey, J; Rehder, C; Kishnani, PS
Published in: Am J Med Genet C Semin Med Genet
February 15, 2012

Enzyme replacement therapy (ERT) for Pompe disease using recombinant acid alpha-glucosidase (rhGAA) has resulted in increased survival although the clinical response is variable. Cross-reactive immunological material (CRIM)-negative status has been recognized as a poor prognostic factor. CRIM-negative patients make no GAA protein and develop sustained high antibody titers to ERT that render the treatment ineffective. Antibody titers are generally low for the majority of CRIM-positive patients and there is typically a better clinical outcome. Because immunomodulation has been found to be most effective in CRIM-negative patients prior to, or shortly after, initiation of ERT, knowledge of CRIM status is important before ERT is begun. We have analyzed 243 patients with infantile Pompe disease using a Western blot method for determining CRIM status and using cultured skin fibroblasts. Sixty-one out of 243 (25.1%) patients tested from various ethnic backgrounds were found to be CRIM-negative. We then correlated the CRIM results with GAA gene mutations where available (52 CRIM-negative and 88 CRIM-positive patients). We found that, in most cases, CRIM status can be predicted from GAA mutations, potentially circumventing the need for invasive skin biopsy and time wasted in culturing cells in the future. Continued studies in this area will help to increase the power of GAA gene mutations in predicting CRIM status as well as possibly identifying CRIM-positive patients who are at risk for developing high antibody titers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Med Genet C Semin Med Genet

DOI

EISSN

1552-4876

Publication Date

February 15, 2012

Volume

160C

Issue

1

Start / End Page

40 / 49

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Mutation
  • Infant, Newborn
  • Infant
  • Immunomodulation
  • Humans
  • Glycogen Storage Disease Type II
  • Genetics & Heredity
  • Fibroblasts
  • Ethnicity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bali, D. S., Goldstein, J. L., Banugaria, S., Dai, J., Mackey, J., Rehder, C., & Kishnani, P. S. (2012). Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet, 160C(1), 40–49. https://doi.org/10.1002/ajmg.c.31319
Bali, Deeksha S., Jennifer L. Goldstein, Suhrad Banugaria, Jian Dai, Joanne Mackey, Catherine Rehder, and Priya S. Kishnani. “Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.Am J Med Genet C Semin Med Genet 160C, no. 1 (February 15, 2012): 40–49. https://doi.org/10.1002/ajmg.c.31319.
Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):40–9.
Bali, Deeksha S., et al. “Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.Am J Med Genet C Semin Med Genet, vol. 160C, no. 1, Feb. 2012, pp. 40–49. Pubmed, doi:10.1002/ajmg.c.31319.
Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, Kishnani PS. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):40–49.
Journal cover image

Published In

Am J Med Genet C Semin Med Genet

DOI

EISSN

1552-4876

Publication Date

February 15, 2012

Volume

160C

Issue

1

Start / End Page

40 / 49

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Mutation
  • Infant, Newborn
  • Infant
  • Immunomodulation
  • Humans
  • Glycogen Storage Disease Type II
  • Genetics & Heredity
  • Fibroblasts
  • Ethnicity